Belharra Therapeutics and Roche Group member Genentech have announced a partnership for the discovery and development of new small molecule medicines across several therapeutic areas.
Under the multi-year partnership, Belharra and Genentech will employ the former’s platform for developing medicines in therapeutic areas including immuno-oncology, oncology, neurodegenerative and autoimmune diseases.
Go deeper with GlobalData
According to the deal, Belharra will discover and assume responsibility for activities related to the early preclinical development of small molecules against targets designated by Genentech.
Genentech will handle late preclinical, clinical activities of such molecules along with their regulatory development and marketing.
Belharra will receive $80m in upfront cash payment and is also eligible for development, commercial, and net sales milestone payments over the course of the partnership.
These payments are expected to be more than $2bn.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAdditionally, Belharra will receive a tiered royalty on the sale of products that are a result of the collaboration by Genentech.
Belharra Therapeutics CEO Jeff Jonker said: “We are excited to work with Genentech and leverage its industry-leading biological acumen to develop novel drug candidates for key therapeutic targets across a range of severe diseases for which patients currently lack adequate treatments.
“Genentech is long recognised for its dedicated pursuit of groundbreaking science to illuminate the drivers of disease and enable the discovery and development of transformational medicines.”
Belharra can also co-develop compounds of certain oncology or immunology programmes that will be designated by Genentech. These compounds will be co-developed through Phase I.
The remaining compounds’ development will be co-funded by Belharra in return for a US cost/profit split and ex-US milestones, as well as royalties.
In July last year, Genentech expanded the exclusive strategic collaboration deal with Bicycle Therapeutics by exercising its second option to start a new programme.
